In this study, we describe a panel of venetoclax combination treatments with enhanced cytotoxic effects on AML cells grown in the absence or presence of bone marrow stroma, including the BCL-XL inhibitor A133825, the MCL1 inhibitor S63845, the BMI1 inhibitor PTC596, the dual PI3K-mTOR inhibitor bimiralisib, the STAT3 inhibitor C-188-9, and the MEK inhibitor trametinib. The gene discussed is MTOR; the disease is acute myeloid leukemia.